Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Dec

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

One in Three Families of Children With ALL Face Financial Hardship During Treatment

Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes

Non-Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL

Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL

New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML